MedImmune Inks Third Reverse Genetics Licensing Deal For Influenza Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also reports positive data from second Phase III study of Synagis follow-on Numax.
You may also be interested in...
MedImmune Files BLA For Pediatric RSV Candidate
PDUFA date for Numax (motavizumab) would be Nov. 30 under standard review.
MedImmune Files BLA For Pediatric RSV Candidate
PDUFA date for Numax (motavizumab) would be Nov. 30 under standard review.
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.